FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021543269> ?p ?o ?g. }

• W2021543269 endingPage "111" @default.
• W2021543269 startingPage "105" @default.
• W2021543269 abstract "Objective We conducted a treatment trial to determine the relative toxicity of FK-506 and cyclosporine A (CSA) in liver transplant recipients. Design Between October 1990 and October 1991, 37 patients were enrolled in an open-labeled, randomized study of two immunosuppressive regimens after liver transplantation. Material and Methods Of the 23 men and 14 women, 20 received FK-506 plus prednisone, and 17 received CSA plus prednisone and azathioprine. Renal function was assessed before and after transplantation (day 1, month 1, month 4, and month 12) by measurements of serum creatinine (SCr) and glomerular filtration rate (GFR) as determined by urinary iothalamate or creatinine clearance (or both). FK-506 trough plasma levels (enzyme immunoassay) were to be maintained between 0.2 and 5.0 ng/mL, and CSA trough blood levels (whole blood high-performance liquid chromatography) were to be maintained between 250 and 400 ng/mL. Severe nephrotoxicity was defined as sudden decreases in urine output to less than 10 mL/h or rapid increases in SCr (more than 0.5 mg/dL daily) that necessitated withdrawal of study medication for more than 48 hours. Mean patient age and values for SCr and GFR were comparable between the two groups at entry. Results Both study groups demonstrated a similar deterioration in renal function during a 12-month follow-up, although patients who received FK-506 had a significantly (P<0.05) lower GFR when measured at 12 months than did patients treated with CSA (45 ± 4 versus 64 ± 6 mL/min per body surface area). Mild nephrotoxicity that responded to decreased drug doses was noted in 9 CSA-treated patients (53%) and 10 FK-506-treated patients (50%). Severe nephrotoxicity that necessitated drug withdrawal occurred in only four patients, all of whom were in the FK-506 group. These severe nephrotoxic reactions to FK-506 occurred early after transplantation, often during intravenous administration of the drug, and were not associated with poor liver allograft function or drug levels outside the therapeutic range. Conclusion Both FK-506 and CSA are significantly nephrotoxic in liver transplant recipients. In this trial, however, we observed an early development of severe nephrotoxic reactions only in some patients who received FK-506. We conducted a treatment trial to determine the relative toxicity of FK-506 and cyclosporine A (CSA) in liver transplant recipients. Between October 1990 and October 1991, 37 patients were enrolled in an open-labeled, randomized study of two immunosuppressive regimens after liver transplantation. Of the 23 men and 14 women, 20 received FK-506 plus prednisone, and 17 received CSA plus prednisone and azathioprine. Renal function was assessed before and after transplantation (day 1, month 1, month 4, and month 12) by measurements of serum creatinine (SCr) and glomerular filtration rate (GFR) as determined by urinary iothalamate or creatinine clearance (or both). FK-506 trough plasma levels (enzyme immunoassay) were to be maintained between 0.2 and 5.0 ng/mL, and CSA trough blood levels (whole blood high-performance liquid chromatography) were to be maintained between 250 and 400 ng/mL. Severe nephrotoxicity was defined as sudden decreases in urine output to less than 10 mL/h or rapid increases in SCr (more than 0.5 mg/dL daily) that necessitated withdrawal of study medication for more than 48 hours. Mean patient age and values for SCr and GFR were comparable between the two groups at entry. Both study groups demonstrated a similar deterioration in renal function during a 12-month follow-up, although patients who received FK-506 had a significantly (P<0.05) lower GFR when measured at 12 months than did patients treated with CSA (45 ± 4 versus 64 ± 6 mL/min per body surface area). Mild nephrotoxicity that responded to decreased drug doses was noted in 9 CSA-treated patients (53%) and 10 FK-506-treated patients (50%). Severe nephrotoxicity that necessitated drug withdrawal occurred in only four patients, all of whom were in the FK-506 group. These severe nephrotoxic reactions to FK-506 occurred early after transplantation, often during intravenous administration of the drug, and were not associated with poor liver allograft function or drug levels outside the therapeutic range. Both FK-506 and CSA are significantly nephrotoxic in liver transplant recipients. In this trial, however, we observed an early development of severe nephrotoxic reactions only in some patients who received FK-506." @default.
• W2021543269 created "2016-06-24" @default.
• W2021543269 creator A5004470985 @default.
• W2021543269 creator A5008493167 @default.
• W2021543269 creator A5024379368 @default.
• W2021543269 creator A5026246814 @default.
• W2021543269 creator A5031764164 @default.
• W2021543269 creator A5037640064 @default.
• W2021543269 creator A5061717823 @default.
• W2021543269 creator A5079447750 @default.
• W2021543269 creator A5090721170 @default.
• W2021543269 creator A5091114867 @default.
• W2021543269 date "1994-02-01" @default.
• W2021543269 modified "2023-10-14" @default.
• W2021543269 title "Nephrotoxic Effects of Primary Immunosuppression With FK-506 and Cyclosporine Regimens After Liver Transplantation" @default.
• W2021543269 cites W2028877735 @default.
• W2021543269 cites W2033077031 @default.
• W2021543269 cites W2070048147 @default.
• W2021543269 cites W2076896665 @default.
• W2021543269 cites W2081319320 @default.
• W2021543269 cites W2090845166 @default.
• W2021543269 cites W2159807891 @default.
• W2021543269 doi "https://doi.org/10.1016/s0025-6196(12)61034-9" @default.
• W2021543269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7508536" @default.
• W2021543269 hasPublicationYear "1994" @default.
• W2021543269 type Work @default.
• W2021543269 sameAs 2021543269 @default.
• W2021543269 citedByCount "108" @default.
• W2021543269 countsByYear W20215432692012 @default.
• W2021543269 countsByYear W20215432692013 @default.
• W2021543269 countsByYear W20215432692014 @default.
• W2021543269 countsByYear W20215432692015 @default.
• W2021543269 countsByYear W20215432692016 @default.
• W2021543269 countsByYear W20215432692017 @default.
• W2021543269 countsByYear W20215432692018 @default.
• W2021543269 countsByYear W20215432692019 @default.
• W2021543269 countsByYear W20215432692021 @default.
• W2021543269 countsByYear W20215432692022 @default.
• W2021543269 countsByYear W20215432692023 @default.
• W2021543269 crossrefType "journal-article" @default.
• W2021543269 hasAuthorship W2021543269A5004470985 @default.
• W2021543269 hasAuthorship W2021543269A5008493167 @default.
• W2021543269 hasAuthorship W2021543269A5024379368 @default.
• W2021543269 hasAuthorship W2021543269A5026246814 @default.
• W2021543269 hasAuthorship W2021543269A5031764164 @default.
• W2021543269 hasAuthorship W2021543269A5037640064 @default.
• W2021543269 hasAuthorship W2021543269A5061717823 @default.
• W2021543269 hasAuthorship W2021543269A5079447750 @default.
• W2021543269 hasAuthorship W2021543269A5090721170 @default.
• W2021543269 hasAuthorship W2021543269A5091114867 @default.
• W2021543269 hasConcept C126189478 @default.
• W2021543269 hasConcept C126322002 @default.
• W2021543269 hasConcept C126894567 @default.
• W2021543269 hasConcept C159641895 @default.
• W2021543269 hasConcept C2776760755 @default.
• W2021543269 hasConcept C2778720950 @default.
• W2021543269 hasConcept C2779134260 @default.
• W2021543269 hasConcept C2779609443 @default.
• W2021543269 hasConcept C2780091579 @default.
• W2021543269 hasConcept C2780252810 @default.
• W2021543269 hasConcept C2780306776 @default.
• W2021543269 hasConcept C2909675724 @default.
• W2021543269 hasConcept C2911091166 @default.
• W2021543269 hasConcept C31785415 @default.
• W2021543269 hasConcept C71924100 @default.
• W2021543269 hasConcept C77411442 @default.
• W2021543269 hasConcept C90924648 @default.
• W2021543269 hasConceptScore W2021543269C126189478 @default.
• W2021543269 hasConceptScore W2021543269C126322002 @default.
• W2021543269 hasConceptScore W2021543269C126894567 @default.
• W2021543269 hasConceptScore W2021543269C159641895 @default.
• W2021543269 hasConceptScore W2021543269C2776760755 @default.
• W2021543269 hasConceptScore W2021543269C2778720950 @default.
• W2021543269 hasConceptScore W2021543269C2779134260 @default.
• W2021543269 hasConceptScore W2021543269C2779609443 @default.
• W2021543269 hasConceptScore W2021543269C2780091579 @default.
• W2021543269 hasConceptScore W2021543269C2780252810 @default.
• W2021543269 hasConceptScore W2021543269C2780306776 @default.
• W2021543269 hasConceptScore W2021543269C2909675724 @default.
• W2021543269 hasConceptScore W2021543269C2911091166 @default.
• W2021543269 hasConceptScore W2021543269C31785415 @default.
• W2021543269 hasConceptScore W2021543269C71924100 @default.
• W2021543269 hasConceptScore W2021543269C77411442 @default.
• W2021543269 hasConceptScore W2021543269C90924648 @default.
• W2021543269 hasIssue "2" @default.
• W2021543269 hasLocation W20215432691 @default.
• W2021543269 hasLocation W20215432692 @default.
• W2021543269 hasOpenAccess W2021543269 @default.
• W2021543269 hasPrimaryLocation W20215432691 @default.
• W2021543269 hasRelatedWork W171560159 @default.
• W2021543269 hasRelatedWork W1989394588 @default.
• W2021543269 hasRelatedWork W1998536172 @default.
• W2021543269 hasRelatedWork W2003277956 @default.
• W2021543269 hasRelatedWork W2005658686 @default.
• W2021543269 hasRelatedWork W2067868355 @default.
• W2021543269 hasRelatedWork W2152841871 @default.
• W2021543269 hasRelatedWork W2286262296 @default.
• W2021543269 hasRelatedWork W2413285244 @default.

• next